PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of alpha-emitting radioisotopes, has just announced the signing of a capacity reservation agreement with Bayer for the supply of actinium-225 (225Ac) starting in the second half of 2024.

This first agreement with a major drug developer reflects PanTera’s unique position to be a reliable, EU-based supplier of 225Ac from this year onward. In 2024, PanTera will continue to work on increasing access to 225Ac for clinical trial needs, as well as on the development of a large-scale, state-of-the-art production facility to address growing global demand.

To read more please visit:

PanTera signs Agreement with Bayer for the Supply of Actinium-225

Source: SCK